Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular weight heparin (RO-14) administered subcutaneously as increasing single doses to healthy male volunteers.

Trial Profile

Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular weight heparin (RO-14) administered subcutaneously as increasing single doses to healthy male volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs RO 14 (Primary)
  • Indications Thrombosis; Venous thromboembolism
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2011 Results published in Thrombosis Research.
    • 15 Jul 2009 Results presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
    • 12 Jan 2009 Actual end date changed from Feb 2008 to Dec 2008 as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top